ArticleFrontiers in immunology2025

Efficacy and prognostic analysis of chemo-immunotherapy after TKI resistance in EGFR-mutant non-small cell lung cancer with TP53 or KRAS co-mutations.

Yuhui Nie et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.